<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663169</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885A2212</org_study_id>
    <nct_id>NCT00663169</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of a Single Dose of ACZ885 in Hospitalized Patients With Acute Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory proof-of-concept study to evaluate the safety and efficacy of
      canakinumab (ACZ885) for inflammation and pain associated with acute gouty arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert Scale</measure>
    <time_frame>72 hours</time_frame>
    <description>72 hours following treatment, patients were asked the question: &quot;How would you rate the improvement in your gout since receiving the study medication?&quot; Patients rated their improvement on the Likert 5-point scale: 1=Excellent, 2=Good, 3=Acceptable,4=Slight and 5=Poor. Improvement was assessed by determining patients who scored a &quot;good&quot; or &quot;excellent&quot; response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-inferiority of a Single Dose of Canakinumab Compared to Dexamethasone During Treatment Period</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence of the Symptoms of Acute Gout (if Applicable) During Treatment Period</measure>
    <time_frame>4 months</time_frame>
    <description>Time to recurrence is defined as from the point of improvement (good to excellent on Likert scale) to recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Walk Independently (if Applicable) During Treatment Period</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Discontinuation of Treatment Due to Adverse Events, Deaths or Serious Adverse Events During the Study</measure>
    <time_frame>4 months</time_frame>
    <description>Additional safety information can be found in the Adverse Event section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein (CRP) From Baseline at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
    <description>Blood was collected at Baseline and Month 4 for CRP to identify the presence of inflammation, to determine its severity, and to monitor response to treatment. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Amyloid A Protein (SAA) From Baseline at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
    <description>Blood was collected at Baseline and Month 4 for SAA to identify the presence of inflammation, to determine its severity, and to monitor response to treatment. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACZ885 (Canakinumab) Pharmacokinetics (PK) Serum Concentration During the Treatment Period</measure>
    <time_frame>Baseline, Days 0.25, 1, 3, 6, 20, 34, 55 and 119</time_frame>
    <description>Blood was collected for ACZ885 (canakinumab) levels at baseline and Days 0.25, 1, 3, 6, 20, 34, 55 and 119. Serum was analyzed by means of a competitive Enzyme linked immunosorbant assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pain Using a Visual Analog Scale at Month 4</measure>
    <time_frame>Baseline, Month 4</time_frame>
    <description>Patients rated their pain on a 100 millimeter (mm) visual analog scale, ranging from no pain (0) to unbearable pain (100). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Took Rescue Medication</measure>
    <time_frame>4 months</time_frame>
    <description>Patients who did not improve by 72 hours post-dose (i.e. patients who show a pain Visual Analog (VAS) decrease of less than 50 % from baseline (Day 1, pre-dose) would have been treated with rescue medication of methylprednisolone 80 mg intravenous or intramuscular once at the discretion of the clinical investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Arthritis, Gouty</condition>
  <arm_group>
    <arm_group_label>Canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>canakinumab</intervention_name>
    <description>10 mg/kg intravenous infusion 250 mL over 2 hours.</description>
    <arm_group_label>Canakinumab</arm_group_label>
    <other_name>ACZ885</other_name>
    <other_name>IlarisÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>12 mg intravenous infusion 50 mL over 30 minutes.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo matching canakinumab</intervention_name>
    <description>5% glucose in water intravenous infusion.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo matching dexamethasone</intervention_name>
    <description>Placebo intravenous infusion.</description>
    <arm_group_label>Canakinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  score over 50 on the 0-100 VAS pain scale

          -  acute, confirmed gout flare for no longer than 3 days

        Exclusion Criteria:

          -  Treatment with biological anti-tumor necrosis factor (anti-TNF) within the past 3
             months

          -  Anti-inflammatory medication for the treatment of acute gout within the previous 24
             hours

          -  Pregnant or breastfeeding women

          -  Major surgery with high infection risk

          -  History of severe allergy to food or drugs

          -  History or risk of tuberculosis

          -  Active infection

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <results_first_submitted>August 30, 2012</results_first_submitted>
  <results_first_submitted_qc>December 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 7, 2013</results_first_posted>
  <disposition_first_submitted>May 22, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 22, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 31, 2012</disposition_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis Gouty</keyword>
  <keyword>ACZ885</keyword>
  <keyword>IL1B protein</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Gouty</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Canakinumab</title>
          <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Dexamethasone</title>
          <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Canakinumab</title>
          <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Dexamethasone</title>
          <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="10.97"/>
                    <measurement group_id="B2" value="46.0" spread="3.46"/>
                    <measurement group_id="B3" value="46.3" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert Scale</title>
        <description>72 hours following treatment, patients were asked the question: âHow would you rate the improvement in your gout since receiving the study medication?â Patients rated their improvement on the Likert 5-point scale: 1=Excellent, 2=Good, 3=Acceptable,4=Slight and 5=Poor. Improvement was assessed by determining patients who scored a âgoodâ or âexcellentâ response.</description>
        <time_frame>72 hours</time_frame>
        <population>Pharmacodynamic set included all randomized subjects with evaluable (or complete) pharmacodynamic parameter data.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert Scale</title>
          <description>72 hours following treatment, patients were asked the question: âHow would you rate the improvement in your gout since receiving the study medication?â Patients rated their improvement on the Likert 5-point scale: 1=Excellent, 2=Good, 3=Acceptable,4=Slight and 5=Poor. Improvement was assessed by determining patients who scored a âgoodâ or âexcellentâ response.</description>
          <population>Pharmacodynamic set included all randomized subjects with evaluable (or complete) pharmacodynamic parameter data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inferiority of a Single Dose of Canakinumab Compared to Dexamethasone During Treatment Period</title>
        <time_frame>72 hours</time_frame>
        <population>Since the study only recruited 6 subjects this analysis was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of a Single Dose of Canakinumab Compared to Dexamethasone During Treatment Period</title>
          <population>Since the study only recruited 6 subjects this analysis was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recurrence of the Symptoms of Acute Gout (if Applicable) During Treatment Period</title>
        <description>Time to recurrence is defined as from the point of improvement (good to excellent on Likert scale) to recurrence.</description>
        <time_frame>4 months</time_frame>
        <population>Since the study recruited only 6 subjects this analysis was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrence of the Symptoms of Acute Gout (if Applicable) During Treatment Period</title>
          <description>Time to recurrence is defined as from the point of improvement (good to excellent on Likert scale) to recurrence.</description>
          <population>Since the study recruited only 6 subjects this analysis was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Walk Independently (if Applicable) During Treatment Period</title>
        <time_frame>4 months</time_frame>
        <population>Since the study recruited only 6 subjects this analysis was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Walk Independently (if Applicable) During Treatment Period</title>
          <population>Since the study recruited only 6 subjects this analysis was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Discontinuation of Treatment Due to Adverse Events, Deaths or Serious Adverse Events During the Study</title>
        <description>Additional safety information can be found in the Adverse Event section.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Discontinuation of Treatment Due to Adverse Events, Deaths or Serious Adverse Events During the Study</title>
          <description>Additional safety information can be found in the Adverse Event section.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinuation from treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-reactive Protein (CRP) From Baseline at Month 4</title>
        <description>Blood was collected at Baseline and Month 4 for CRP to identify the presence of inflammation, to determine its severity, and to monitor response to treatment. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Month 4</time_frame>
        <population>Pharmacodynamic set included all randomized patients with evaluable (or complete) pharmacodynamic parameter data.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein (CRP) From Baseline at Month 4</title>
          <description>Blood was collected at Baseline and Month 4 for CRP to identify the presence of inflammation, to determine its severity, and to monitor response to treatment. A negative change from baseline indicates improvement.</description>
          <population>Pharmacodynamic set included all randomized patients with evaluable (or complete) pharmacodynamic parameter data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.23" spread="16.822"/>
                    <measurement group_id="O2" value="-30.30" spread="51.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Amyloid A Protein (SAA) From Baseline at Month 4</title>
        <description>Blood was collected at Baseline and Month 4 for SAA to identify the presence of inflammation, to determine its severity, and to monitor response to treatment. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Month 4</time_frame>
        <population>Pharmacodynamic set included all randomized patients with evaluable (or complete) pharmacodynamic parameter data.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Amyloid A Protein (SAA) From Baseline at Month 4</title>
          <description>Blood was collected at Baseline and Month 4 for SAA to identify the presence of inflammation, to determine its severity, and to monitor response to treatment. A negative change from baseline indicates improvement.</description>
          <population>Pharmacodynamic set included all randomized patients with evaluable (or complete) pharmacodynamic parameter data.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-579.980" spread="563.7449"/>
                    <measurement group_id="O2" value="-260.327" spread="463.8600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACZ885 (Canakinumab) Pharmacokinetics (PK) Serum Concentration During the Treatment Period</title>
        <description>Blood was collected for ACZ885 (canakinumab) levels at baseline and Days 0.25, 1, 3, 6, 20, 34, 55 and 119. Serum was analyzed by means of a competitive Enzyme linked immunosorbant assay (ELISA).</description>
        <time_frame>Baseline, Days 0.25, 1, 3, 6, 20, 34, 55 and 119</time_frame>
        <population>Pharmacodynamic set included all randomized subjects with evaluable (or complete) pharmacodynamic parameter data.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>ACZ885 (Canakinumab) Pharmacokinetics (PK) Serum Concentration During the Treatment Period</title>
          <description>Blood was collected for ACZ885 (canakinumab) levels at baseline and Days 0.25, 1, 3, 6, 20, 34, 55 and 119. Serum was analyzed by means of a competitive Enzyme linked immunosorbant assay (ELISA).</description>
          <population>Pharmacodynamic set included all randomized subjects with evaluable (or complete) pharmacodynamic parameter data.</population>
          <units>Î¼g/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0.25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.5" spread="143.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.5" spread="26.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3">Standard deviation not calculated- data available for only 1 participant.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.6" spread="41,532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.37" spread="11.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.87" spread="13.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.67" spread="8.4884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 119</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.643" spread="4.6151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pain Using a Visual Analog Scale at Month 4</title>
        <description>Patients rated their pain on a 100 millimeter (mm) visual analog scale, ranging from no pain (0) to unbearable pain (100). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, Month 4</time_frame>
        <population>Pharmacodynamic set included all randomized subjects with evaluable (or complete) pharmacodynamic parameter data.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain Using a Visual Analog Scale at Month 4</title>
          <description>Patients rated their pain on a 100 millimeter (mm) visual analog scale, ranging from no pain (0) to unbearable pain (100). A negative change from baseline indicates improvement.</description>
          <population>Pharmacodynamic set included all randomized subjects with evaluable (or complete) pharmacodynamic parameter data.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62.0" spread="3.61"/>
                    <measurement group_id="O2" value="-65.7" spread="17.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Took Rescue Medication</title>
        <description>Patients who did not improve by 72 hours post-dose (i.e. patients who show a pain Visual Analog (VAS) decrease of less than 50 % from baseline (Day 1, pre-dose) would have been treated with rescue medication of methylprednisolone 80 mg intravenous or intramuscular once at the discretion of the clinical investigator.</description>
        <time_frame>4 months</time_frame>
        <population>All participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Canakinumab</title>
            <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Dexamethasone</title>
            <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Took Rescue Medication</title>
          <description>Patients who did not improve by 72 hours post-dose (i.e. patients who show a pain Visual Analog (VAS) decrease of less than 50 % from baseline (Day 1, pre-dose) would have been treated with rescue medication of methylprednisolone 80 mg intravenous or intramuscular once at the discretion of the clinical investigator.</description>
          <population>All participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Canakinumab</title>
          <description>Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Dexamethasone</title>
          <description>Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

